CD19 (CAR T)

CD19 is a surface glycoprotein belonging to the immunoglobulin (Ig) superfamily that can act as a central positive response regulator in
B cells.1-3 CD19 is expressed during normal B-cell development, and the expression is maintained following malignant transformation of B cells.2-4
The specific expression of CD19 in B-cell lineage lymphomas and leukemias makes CD19 a promising target antigen in B-cell malignancies, like non-Hodgkin lymphomas, through investigational therapies such as chimeric antigen receptor (CAR) T cell therapy.2-4

CD19 molecular pathway research

View areas of research related to CD19 (CAR T)

References

  1. Scheuermann RH and Racila E. Leuk Lymphoma. 1995;18:385-397. PMID: 8528044
  2. Wang K, et al. Exp Hematol Oncol. 2012;1:36. PMID: 23210908
  3. Naddafi R, Davami F. IJMCM. 2015;4:143-151. PMID: 26629482
  4. Maude SL, et al. Blood. 2015;125:4017-4023. PMID: 25999455